Fluvastatin Plus Dipyridamole Suppresses Canine Hemangiosarcoma Growth in Patient‐Derived Xenograft Models Through Lactate Dehydrogenase‐Associated Cholesterol/Lipid Metabolism
Veterinary and Comparative Oncology · 2026-12 · 24 (4) · 769-780
DOI: 10.1111/vco.70097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, online erschienen am 10.08.2026. Verfasst von Tamami Suzuki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Comparative Pathology, Department of Clinical Sciences, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, Japan. Hauptthemen laut MEDLINE: Fluvastatin, Dog Diseases, Hemangiosarcoma, Dipyridamole. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, >Faculty of Veterinary Medicine, Hokkaido University, Donations from the general public.
Abstract (Originalsprache)
Tumour cells commonly exhibit aerobic glycolysis and produce lactate despite oxygen availability. Lactate dehydrogenase (LDH) catalyses pyruvate‐lactate interconversion and regulates intracellular lactate levels. Endothelial cells also depend on glycolysis for ATP production, which prompted us to investigate LDH in canine hemangiosarcoma (HSA), a malignant endothelial tumour. We inhibited LDH with (R)‐GNE‐140 or sodium oxamate in two canine HSA cell lines (HU‐HSA‐2 and HU‐HSA‐3) and generated HU‐HSA‐3 clones with knockout of LDHA or LDHB to evaluate the effects of LDH perturbation. (R)‐GNE‐140 and sodium oxamate suppressed proliferation and reduced global histone lactylation levels in both cell lines. mRNA‐sequencing (mRNA‐seq) of (R)‐GNE‐140‐treated HU‐HSA‐2 cells identified cholesterol/lipid metabolism‐related gene sets among the top negatively enriched pathways. Representative cholesterol/lipid metabolism genes such as SREBF2 , SQLE and LDLR responded differently depending on cell lines and inhibitors. (R)‐GNE‐140 decreased these genes in HU‐HSA‐2 but not HU‐HSA‐3, whereas sodium oxamate decreased them in HU‐HSA‐3 with limited effects in HU‐HSA‐2. In HU‐HSA‐3, LDHA and LDHB knockout clones decreased SREBP2 expression and reduced the number of lipid droplets. Fluvastatin, a cholesterol metabolism inhibitor, inhibited HSA cell growth in vitro but did not significantly suppress tumour growth in two HSA patient‐derived xenograft (PDX) models. In contrast, combined fluvastatin and dipyridamole treatment inhibited proliferation in vitro and tumour growth in PDX models. Collectively, these results suggest a context‐dependent association between LDH and cholesterol/lipid metabolism in canine HSA cell lines and provide a rationale for further evaluation of combined cholesterol pathway inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Comparative Pathology, Department of Clinical Sciences, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
- Translational Research Unit, Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
- Cancer Research Unit, One Health Research Center, Hokkaido University, Sapporo, Hokkaido, Japan.
ORCID-Profile: Takashi Kimura, Keisuke Aoshima
Förderung
- Japan Society for the Promotion of Science
- >Faculty of Veterinary Medicine, Hokkaido University
- Donations from the general public
Zitieren
APA
Suzuki, T., Tanaka, S., Kishimoto, K., Goto, T., Yamazaki, J., Kimura, T., & Aoshima, K. (2026). Fluvastatin Plus Dipyridamole Suppresses Canine Hemangiosarcoma Growth in Patient‐Derived Xenograft Models Through Lactate Dehydrogenase‐Associated Cholesterol/Lipid Metabolism. Veterinary and Comparative Oncology, 24(4), 769-780. https://doi.org/10.1111/vco.70097
Vancouver
Suzuki T, Tanaka S, Kishimoto K, Goto T, Yamazaki J, Kimura T, et al. Fluvastatin Plus Dipyridamole Suppresses Canine Hemangiosarcoma Growth in Patient‐Derived Xenograft Models Through Lactate Dehydrogenase‐Associated Cholesterol/Lipid Metabolism. Veterinary and Comparative Oncology. 2026;24(4):769-780. doi:10.1111/vco.70097
BibTeX
@article{Suzuki2026,
author = {Suzuki, Tamami and Tanaka, Suzune and Kishimoto, Keika and Goto, Takuma and Yamazaki, Jumpei and Kimura, Takashi and Aoshima, Keisuke},
title = {Fluvastatin Plus Dipyridamole Suppresses Canine Hemangiosarcoma Growth in Patient‐Derived Xenograft Models Through Lactate Dehydrogenase‐Associated Cholesterol/Lipid Metabolism},
journal = {Veterinary and Comparative Oncology},
year = {2026},
volume = {24},
number = {4},
pages = {769--780},
doi = {10.1111/vco.70097}
}
EUVIMED